Commemorating 25 years of fighting pancreatic cancer
Learn More

Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • COVID-19 Resources
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Caregivers
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Financial Aid
    • Resources →
      • Symptom Management Workbook
      • Guidelines for Patients: Pancreatic Cancer
      • Creating Your Health Care Team
      • A Virtual Advocate
      • Patient Tools
  • HOW YOU CAN HELP
    • You Can Help Funds
    • Host Your Own Event
    • Event Calendar
    • Get Inspired
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • Other Ways to Give →
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Planned Giving
      • Car Program
  • SEARCH
Home / Research / Seed Grant Program / Seed Grant Recipients / Yaroslav Teper, PhD

Yaroslav Teper, PhD

Yaroslav Teper, PhD
Yaroslav Teper, PhD
Assistant Project Scientist

General Surgery

University of California, Los Angeles (UCLA)
Los Angeles, CA

Comparison of acinar and ductal cell driven PDAC development promoted by obesity

Overview

Aim: Biology

Pancreatic ductal adenocarcinoma (PDAC) continues to be one of the most lethal human diseases, with an overall 5-year survival rate of just around 10%. An estimated 48,220 people in the US will succumb to this disease in 2021, putting pancreatic cancer as the third leading cause of cancer mortality in women and men combined. Alarmingly, the incidence of pancreatic cancer has increased over the last years.

A detailed understanding of modifiable risk factors, e.g. obesity, will most likely guide the rapid implementation of new preventive strategies. We have confirmed that PDACs differ in histology, severity, and outcome depending on whether they arise from acinar or ductal cells. It is also known that obesity has been shown to promote and accelerate PDAC development. However, the distinctive impact of obesity on PDAC arising from acinar versus ductal cells is unknown.

While acinar-derived PDAC develops through the usual acinar-ductal-metaplasia (ADM)-pancreatic intraepithelial neoplasia (PanIN)-PDAC sequence, duct-derived PDAC developed in the absence of PanINs or other mucinous precursors indicating an alternative progression route of PDAC. Importantly, mice with duct-derived PDAC had a significantly shortened survival suggesting a differential prognosis of PDAC of different origins. It has not been investigated so far whether Diet-Induced-Obesity (DIO) can also promote PDAC development in a duct-derived PDAC model. In this aim we will investigate and compare the effects of DIO on acinar- and duct-derived PDAC development in inducible KrasG12D mouse models. We hypothesize that DIO can promote PDAC development in a duct-derived model of PDAC and that PDAC development in a duct-derived model promoted by DIO progresses faster and more aggressive compared to an acinar derived model.

In this current study, the efficacy of obesity on PDAC development in acinar cell and ductal cell derived PDACs will be compared. The proposed exploratory studies are of great significance as they will illuminate PDAC biology, detect potential differential responses to risk factors (obesity), and could identify better markers for patient stratification and treatment options.

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Contact Us